

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/004041-2024>

Planning

Provisions of an Oesophageal Cell Collection Device (OCCD) and service delivery to pathology lab, pathology service and pathology reporting to NHS Scotland

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

F01: Prior information notice

Prior information only

Notice identifier: 2024/S 000-004041

Procurement identifier (OCID): ocds-h6vhtk-0437e1

Published 7 February 2024, 12:13pm

Section I: Contracting authority

I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

Gyle Square (NSS Head Office), 1 South Gyle Crescent

Edinburgh

EH12 9EB

Email

steve.graham@nhs.scot

Telephone

+44 1698794410

Country

United Kingdom

NUTS code

UKM - Scotland

Internet address(es)

Main address

<http://www.nss.nhs.scot/browse/procurement-and-logistics>

Buyer's address

https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Provisions of an Oesophageal Cell Collection Device (OCCD) and service delivery to pathology lab, pathology service and pathology reporting to NHS Scotland

Reference number

NP199-23

II.1.2) Main CPV code

- 85111800 - Pathology services

II.1.3) Type of contract

Services

II.1.4) Short description

This requirement is for an Oesophageal Cell Collection Device (OCCD) diagnostic service inclusive of delivery of pathology lab test to initiating clinician, which must be able to be integrated into the NHS, across Scotland with the aim of improving the patient journey, improving outcomes and reducing the requirement for traditional hospital-based procedures.

As outlined above, Supplier must be able to provide holistic service of an Oesophageal Cell Collection Device (OCCD) and diagnostic service inclusive of delivery of pathology lab test.

II.1.5) Estimated total value

Value excluding VAT: £700,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 85111800 - Pathology services

II.2.3) Place of performance

NUTS codes

- UKM - Scotland

Main site or place of performance

Any or all locations of NHS Scotland.

II.2.4) Description of the procurement

This requirement is for an Oesophageal Cell Collection Device (OCCD) diagnostic service inclusive of delivery of pathology lab test to initiating clinician, which must be able to be integrated into the NHS, across Scotland with the aim of improving the patient journey, improving outcomes and reducing the requirement for traditional hospital-based procedures.

As outlined above, Supplier must be able to provide holistic service of an Oesophageal Cell Collection Device (OCCD) and diagnostic service inclusive of delivery of pathology lab test.

II.3) Estimated date of publication of contract notice

11 March 2024

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section VI. Complementary information

VI.3) Additional information

Following a review of Upper GI endoscopy diagnostic testing, it was identified there is a requirement for a minimally invasive diagnostic test, without the use of sedation in patients who require screening or surveillance of Oesophageal pathologies such as Barrett's Oesophagus (BE known pre-malignant lesion for oesophageal adenocarcinoma). Patients with reflux predominant upper GI symptoms who have been referred for urgent Upper GI endoscopy with concern of pre or early oesophageal cancer and/or patient's with known Barrett's oesophagus who are at risk of oesophageal cancer with progressive symptoms and/or who have had significant delay in their upper GI endoscopy would be eligible for the diagnostic test. The Pathology laboratory test should include –TFF3 (Trefoil Factor 3) biomarker (BE specific marker), and p53 and atypia reporting to define high-risk criteria.

NHS Scotland has made the decision to implement a national approach for the Provision of an Oesophageal Cell Collection Device (OCCD) and service delivery to pathology lab, pathology service and pathology reporting, in a 'Once for Scotland' approach. This procurement is to identify a holistic service provider that will be implemented across all NHS Scotland health boards for this provision.

NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at

https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=757026.

(SC Ref:757026)